Colistimethate Sodium Dosing and Nephrotoxicity among in-Patients at Tertiary Care Hospital Karachi, Pakistan

Javeria Mohammad Arif1, Mirza Tasawer Baig1*, Uzma Shahid2, Ambreen Huma3, Samina Sheikh1, Aisha Jabeen4, Quratul Ain Pirzada5, Saba Shaikh1, Arva Rawat1, Abdul Kadir4 and Muhammad Kashif6

1Department of Pharmacy Practice, Faculty of Pharmacy, Ziauddin University, Karachi, Pakistan.
2Surecell Australian Stem Cell Clinic, Karachi, Pakistan.
3Department of Pharmacognosy, Faculty of Pharmacy, Ziauddin University, Karachi, Pakistan.
4Department of Pharmacology, Faculty of Pharmacy, Ziauddin University, Karachi, Pakistan.
5Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Jinnah University for Women, Karachi, Pakistan.
6Drug Regulatory Authority of Pakistan, Islamabad, Pakistan.

Authors' contributions

This work was carried out in collaboration among all authors. Authors JMA, MTB, US, AH, SS and AJ designed the study, performed the statistical analysis, wrote the protocol and wrote the first draft of the manuscript. Authors QAP, SS and AR managed the analyses of the study. Authors AK and MK managed the literature searches. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/JPRI/2021/v33i1631297

Editor(s):
(1) Dr. Asmaa Fathi Moustafa Hamouda, Jazan University, Saudi Arabia.

Reviewer(s):
(1) Deepak Kumawat, Oriental University, India.
(2) Dalip Singh Rathore, Saurashtra University, India.

Complete Peer review History: http://www.sdiarticle4.com/review-history/66502

Received 10 January 2021
Accepted 17 March 2021
Published 25 March 2021

ABSTRACT

Introduction: Colistimethate sodium (CMS) is a polymyxin group of antibiotics which were throw out for many years, due to their potential adverse reaction neurotoxicity and nephrotoxicity. The different guidelines were reported regarding CMS dosing some based on Creatinine clearance (CrCl) and some on weight and CrCl. There are many discrepancies in the prevalence of nephrotoxicity that has been reported which included various definitions of acute renal injury and

*Corresponding author: E-mail: mirzatasawerbaig@gmail.com;
many CMS doses used in a variety of literature. In EMA guideline they suggested the dose as 9 MIU which is equivalent to 300 mg of CBA given as a maintenance dose with normal renal function patients. In FDA standard dosing of CMS remains 5 mg/kg CBA per day used and also dose is dependent on patient weight. The aim of this study was to evaluate the dosing criteria of colistimethate sodium associated with nephrotoxicity. 

Methodology: A prospective observational study was conducted in private sector tertiary care hospital in Karachi, Pakistan, for duration of six months from July 2020 to December 2020. Sample size was comprised of 157 patients, calculated at 35% prevalence, 95% Confidence Interval and 7% margin of error. Patient included were ≥ 18 years of age, who have received intravenous CMS therapy for greater than 48 hours. Patients having an acute kidney injury or on dialysis (at start of therapy) were excluded. Loading dose and daily dose of CMS was calculated by using actual body weight and Creatinine clearance (CrCl). Cockcroft and Gault equation was used to estimate CrCl before and after the therapy. Nephrotoxicity was assessed by using the RIFLE criteria. SPSS-20 was used for frequency distribution and percentage calculation to show categorical variable.

Results: Among 157 enrolled patients, 101 (64.3%) were male and 56(35.7%) were female (Table 1). Table 2. represents that 68(43.3%) patients were admitted in intensive care unit (ICU) and 89(56.7%) were in medicinal ward; 22.9% patients were in between the age range 60-70 years (Table 3). Among all patients 63(40.1%) patients were at risk of nephrotoxicity, 27(17.2%) patients were developing injury and 14(8.9%) patients were diagnosed to kidney failure and 53(33.8%) patients were found not to developed nephrotoxicity (Table 4). Table 5 exhibits that 48.4% of the patients were receiving dose of CMS using EMA guideline while 51.6% patients were receiving dose of CMS 2.5-5 mgCBA/kg/day according to FDA. Nephrotoxicity was high among FDA regimen (44.5%).

Conclusion: It was concluded that CMS dosing criteria have a significant impact on nephrotoxicity. Close monitoring of renal function, particularly the first week of CMS therapy should be considered to evaluate the renal toxicity of CMS.

Keywords: Colistimethate sodium; neurotoxicity; nephrotoxicity; FDA guidelines; EMA guidelines; Creatinine clearance; multi-drug resistance gram negative bacteria.

1. INTRODUCTION

Colistimethate sodium (CMS) is a polymyxin group of antibiotics which were threw out for many years, due to their potential adverse reaction neurotoxicity and nephrotoxicity [1]. Unfortunately, the incidence of infection caused by multi-drug resistance gram negative bacteria (MDRGNB) like, “Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa”. The World Health Organization has announced that this group of bacteria were belongs to the microorganism in the most critical main concern group for research and development of new anti-bacterial agent [2]. With the introduction of polymyxin to clinical practice, CMS was marketed as offering greater or equal anti-bacterial potency as compared to polymyxin B and CMS was supposed to serious toxic effect in patient because larger dose of CMS were required for effectiveness and thus nephrotoxicity rate were increased [3]. Acute kidney injury(AKI) is a potential life threatening condition, approximately 7% of all hospitalized patients developed AKI with the higher prevalence in intensive care unit about 20% [4]. In particular, acute kidney injury (AKI) is considered to be dose and duration dependent and it is expected to occur in approximately 15%-25% of cases receiving CMS therapy. The pathophysiology of colistin-associated nephrotoxicity is multifactorial [5]. The incidence of AKI during treatment is related with worse prognosis, including higher mortality rates [6,7]. Among patients who were prone to AKI during CMS treatment has been higher incidence of chronic renal failure [8]. The RIFLE criteria (risk.injury.failure.end stage kidney disease) is anauthorized tool used in literature to estimate drug induced AKI [9,10].

The dose of intravenous CMS is recommended by the manufacturers in the "united states" is 2.5-5 mg/kg of colistin base that is "75,000-150,000IU/kg" per day divided into 2-4 equal doses. For adult patients with normal kidney function. The dosage of united kingdom is "4-6 mg/kg(50,000-75,000 IU/kg)"per day with body weight less than and equal to 60kg in three divided doses for adults [11]. Registered brands of Colistimethate Sodium used in Pakistan are; Coliate (One MIU), Colistim (One MIU).Its each vial contains Colistimethate Sodium (80 mg) and
Colistin base activity (CBA) is 30 mg which is also equal to One Million International Units (MIU) per vial Colistimethate Sodium. Its intravenous administration is to be prepared in 0.9% normal saline or 5% dextrose water (100ml) at run rate of 30 minutes [12]. The different guidelines were reported regarding CMS dosing some based on creatinine clearance (CrCl) and some on weight and (CrCl). There are many discrepancies in the prevalence of nephrotoxicity that has been reported which included various definitions of acute renal injury and many CMS doses used in a variety of literature [13]. In EMA guideline they suggested that (9MIU) which is equivalent to 300 mg of CBA given as a maintenance dose with normal renal function patients. In FDA standard dosing of CMS remains 5 mg/kg CBA per day used and also dose is dependent on patient weight. Although the package insert recommended dose based on IBW (ideal body weight) but few active clinicians prefer to use the body weight of patients or an adjusted body weight for achieve higher serum concentration [14]. The FDA and EMA update their dosing recommendation in 2014 significant variation exists in their dosing regimen, the EMA regimen included 9MU maintenance dose and based on CrCl to achieve a desired steady-state concentration of CMS as compared with FDA [15,16]. In this study, we examined the incidence of CMS induced nephrotoxicity in our patient’s population and evaluated the association between CMS dosing and the incidence of nephrotoxicity. The aim of this study is to evaluate that which risk factors and dosing regimen effect nephrotoxicity.

2. METHODOLOGY

This was a prospective observational study conducted at Tertiary Care Private Sector Hospital in Karachi, Pakistan, among patients, who were prescribed with intravenous Colistimethate Sodium. Clinical data was obtained from the In-patients’ bed side file. Patients were enrolled after having informed consent. The therapy with CMS was noted at the start of antibiotic (Colistimethate Sodium) till the patient health recovered or discharged from hospital. Demographic data included age, gender, weight of the patients. Loading dose and daily dose of Colistimethate Sodium was calculated by the Principle Investigator, using actual body weight and Creatinine clearance (CrCl). Cockcroft and Gault equation was used to estimate CrCl before and after the therapy [17]. Nephrotoxicity was assessed by using the RIFLE criteria [9,13,18]. Duration of the study was 6 months from July 2020 to December 2020. Sample size of 157 In-patients was calculated at 35% prevalence, 95% Confidence Interval and 7% margin of error [19]. In-patient with age ≥ 18 years and were prescribed intravenous Colistimethate Sodium therapy for greater than 48 hours, were included. Patients who have Colistimethate Sodium therapy only one admission episode were not included in the study. Patients who were pregnant, or received inhaled colistin therapy and patients having an acute kidney injury or on dialysis at start of therapy were also excluded. SPSS-20 was used for data analysis. Frequencies and percentage were calculated.

3. RESULT

Among 157 enrolled patients, 101 (64.3%) were male and 56(35.7%) were female (Table 1). Table 2 represents 68(43.3%) patients were admitted in intensive care unit (ICU) and 89(56.7%) patients were admitted in medicinal ward; 22.9% patients were in between the age range 60-70 years (Table 3). Among all patients 63(40.1%) patients were at risk of nephrotoxicity, 27(17.2%) patients were developing injury and 14(8.9%) patients were diagnosed to kidney failure and 53(33.8%) patients were found not to developed nephrotoxicity (Table 4). Table 5 exhibits that 48.4% of the patients were receiving dose of CMS using EMA guideline while 51.6% patients were receiving dose of CMS 2.5-5 mgCBA/kg/day according to FDA. Nephrotoxicity was high among FDA regimen (44.5%).

4. DISCUSSION

Nephrotoxicity is a major cause of high mortality and morbidity worldwide [20]. Nephrotoxicity

| Gender | Frequency | Percent |
|--------|-----------|---------|
| Male   | 101       | 64.3    |
| Female | 56        | 35.7    |
| Total  | 157       | 100.0   |
related to CMS administration is a major challenge for clinicians now-a-day. As shown in Table 2, 43.3% patients were admitted in ICU and 56.7% patients were admitted in medicinal ward, however, Omrani et al. expressed admission in ICU as the main independent factor [21]. Our study revealed that male ratio was significantly high as compared to female in diagnosis of kidney injury; males are more prone to nephrotoxicity. Rauf et al. study also reported that males had a high rate of acute kidney injury [22]. In another study of Horkan et al. they found a significant association between sex and acute kidney injury [23]. In our study, the increase rate of nephrotoxicity was found in age group 40-80 years. Chao et al. also reported that in CMS administration the frequency of nephrotoxicity was also high in old aged patients because of age related functional deterioration of kidney [24]. Rodrigo et al. found that age related factor is more prone to kidney injury. They also stated that mechanical ventilation and glomerular filtration rate are independent predictors of nephrotoxicity associated with CMS [25].

In a present study, we included total 157 patients in which 63(40.1%) patients were at risk of nephrotoxicity, 27(17.2%) patients were diagnosed to kidney failure and 53(33.8%) patients did not develop nephrotoxicity (Table 4). Pogue et al. reported 17% rate of injury which is similar to our study. They concluded that predictor of nephrotoxicity is due to high dose greater than and equal to 5 mg/kg/day [14]. In another study of Al-Abdulkarim et al. 40.6% patients were on risk which is very close to our study, they also stated that nephrotoxicity increased due to inappropriate dosing and elderly age [10]. In our study we found that 153(97.5%) patients were

| Admission Ward          | Frequency | Percent |
|-------------------------|-----------|---------|
| Intensive Care Unit     | 68        | 43.3    |
| Medicinal Ward          | 89        | 56.7    |
| Total                   | 157       | 100.0   |

Table 3. Age of patients

| Age of patients | Frequency | Percent |
|-----------------|-----------|---------|
| 18-28 year      | 9         | 5.7     |
| 29-38 year      | 15        | 9.6     |
| 39-48 year      | 24        | 15.3    |
| 49-58 year      | 26        | 16.6    |
| 59-68 year      | 28        | 17.8    |
| 69-78 year      | 36        | 22.9    |
| 79-88 year      | 17        | 10.8    |
| 89 or Above     | 2         | 1.3     |
| Total           | 157       | 100.0   |

Table 4. Rifle criteria of patients

| Rifle criteria | Frequency | Percent |
|----------------|-----------|---------|
| No Risk        | 53        | 33.8    |
| Risk           | 63        | 40.1    |
| Injury         | 27        | 17.2    |
| Failure        | 14        | 8.9     |
| Total          | 157       | 100.0   |

| No. of Patients | CMS Dose 3MU Every 8 Hourly(EMA) | CMS Dose 2.5-5mgca/Kg/Day(FDA) |
|-----------------|----------------------------------|---------------------------------|
| 157             | 76(48.4%)                        | 81(51.6%)                       |
| Rate of Nephrotoxicity | 34(21.6%)                 | 70(44.5%)                       |

Table 5. Dose calculation strategy of CMS
receiving 9MU loading dose following (3MU) CMS every 8 hourly which is equivalent to 300 mg CBA/day. It was found that 48.4% of the patients were receiving the dose of the drug based on EMA guideline and 51.6% patients were receiving the dose based on CMS 2.5-5 mg CBA/kg/day according to FDA (Table 5). It was observed that clinicians prefer different dosing criteria; some were preferring according to creatinine clearance (CrCl>80 ml/min CMS dose 300 mgCBA/day) and some were preferring 2.5-5 mg/kg/day and use actual body weight for dose calculation instead of ideal body weight. In this study we found that nephrotoxicity was high in patients who were prescribed according to FDA regimen (44.5%), which may be due the reason that the dose is adjusted according to serum creatinine or CrCl and using actual body weight instead of using ideal body weight, high dose given to patient in aspect of creatinine clearance (CrCl). Our study revealed that 15 patients had low CrCl before therapy but were receiving high dose of CMS. Falagas et al. also concluded that administration of CMS dose was statistically correlated with serum creatinine [11]. Among patients, who received dose according to EMA criteria, their dose should be adjusted according to creatinine clearance. In a study of Almutairy et al. the incidence of CMS associated nephrotoxicity was high due higher daily dose of CMS. They stated that more than 75% of the patient were on stage 1 and stage 2 AKI [26]. In another study of Omrani et al. high dose of CMS therapy associated with high rate of nephrotoxicity [21]. De Ryke et al. study also reported that daily high dose of CMS increased the incidence of nephrotoxicity and was using actual body weight for dose calculation, similar to our study, they also stated that use of ideal body weight for calculating the dose may be less nephrotoxic [27].

5. CONCLUSION

It was concluded that Colistemethate Sodium dosing criteria was found to have significant impact on nephrotoxicity. It was recommended that close monitoring of renal function, particularly the first week of CMS therapy should be consider evaluating the renal toxicity of CMS. Dose should be calculated on the basis of ideal body weight and creatinine clearance of the patients to avoid the risk of nephrotoxicity. Further analysis must be carry on to recognize the optimal dose of CMS for the purpose of safety, efficacy and toxicity.

CONSENT

Patients were enrolled after having written informed consent.

ETHICAL APPROVAL

Ethical approval was taken from Ethics Review Committee (ERC) of Ziauddin University (Protocol No. 1820120JAPHA).

ACKNOWLEDGEMENT

We are thankful to the management of Dr. Ziauddin Hospital and Ethics Review Committee for supporting the study.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Aitullina A, Purviňa S, Krūmiņa A. Colistin co-administration with other nephrotoxins: experience of teaching hospital of Latvia. International Journal of Clinical Pharmacy. 2020;1-9.
2. Shrivastava SR, Shrivastava PS, Ramasamy J. World health organization releases global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. Journal of Medical Society. 2018;32(1):76.
3. Velkov, Tony, et al. History, Chemistry and Antibacterial Spectrum. Polymyxin Antibiotics: From Laboratory Bench to Bedside. Springer, Cham. 2019;15-36.
4. Yong K, Dogra G, Boudville N, Pinder M, Lim W. Acute kidney injury: controversies revisited. International Journal of Nephrology; 2011.
5. Bellos I, Pergialiotis V, Frountzas M, Kontzoglou K, Daskalakis G, Perrea DN. Efficacy and safety of colistin loading dose: A meta-analysis. Journal of Antimicrobial Chemotherapy; 2020.
6. Baradaran S, Black DJ, Keyloun KR, Hansen RN, Gillard PJ, Devine, B. The Impact of Acute Kidney Injury on the Risk of Mortality and Health Care Utilization Among Patients Treated With Polymyxins for Severe Gram-Negative Infections. In
open forum infectious diseases. US: Oxford University Press. 2018;5(8):191.
7. Rigatto MH, Behle TF, Falci DR, Freitas T, Lopes NT, Nunes M, et al. Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: A multicentre prospective cohort study. Journal of Antimicrobial Chemotherapy. 2015;70(5):1552-1557.
8. Gomes EC, Falci DR, Bergo P, Zavascki AP, Rigatto MH. Impact of polymyxin-B-associated acute kidney injury in 1-year mortality and renal function recovery. International Journal of Antimicrobial Agents. 2018;52(1):86-89.
9. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure—definition, outcome measures, animal models, fluid therapy and information technology needs: The Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Critical Care. 2004;8(4):R204.
10. Al Abdulkarim DA, Alzuwayed OA, Al Ammari M, Al Halwan S, Al Maklafi N, Thomas, A. Colistin-induced Nephrotoxicity in a Tertiary Teaching Hospital. Saudi Journal of Kidney Diseases and Transplantation. 2020;31(5):1057.
11. Falagas ME, Kasiakou SK, Saravolatz LD. Colistin: The revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clinical Infectious Diseases. 2015;60(9):1333-1341.
12. Hassan MM, Gaifor Z, Al Zakwani IS, 2018. Incidence and risk factors of nephrotoxicity in patients on colistimethate sodium. International Journal of Clinical Pharmacy. 2018;40(2):444-449.
13. Pike M, Saltiel E. Colistin-and polymyxin-induced nephrotoxicity: focus on literature utilizing the RIFLE classification scheme of acute kidney injury. Journal of Pharmacy Practice. 2014;27(6):554-561.
14. Pogue JM, Lee J, Marchaim D, Yee V, Zhao JJ, Chopra T, et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system, Clinical Infectious Diseases. 2011;53(9):879-884.
15. Food and Drug Administration. Coly-Mycin®M Parenteral (Colistimethate for Injection, USP); 2020. Available:https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050108s026lbl Accessed: on 29 July 2020.
16. Nation RL, Garonzik SM, Li J, Thamlikitkul, V, Giamarelos Bourboulis EJ, Paterson D, et al. Updated US and European dose recommendations for intravenous colistin: how do they perform?. Clinical Infectious Diseases. 2016;62(5):552-558.
17. Cockcroft DW, Gault H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41.
18. Garzotto F, Piccinni P, Cruz D, Gramaticopolo S, Dal Santo M, Aneloni G. et al. RIFLE-based data collection/management system applied to a prospective cohort multicenter Italian study on the epidemiology of acute kidney injury in the intensive care unit. Blood Purification. 2011;31(1-3):159-171.
19. Kaddourah A, Basu RK, Bagshaw SM, Goldstein SL, Epidemiology of acute kidney injury in critically ill children and young adults. New England Journal of Medicine. 2017;376(1):11-20.
20. Kwon JA, Lee JE, Huh W, Peck KR, Kim YG, Kim DJ, Oh HY. Predictors of acute kidney injury associated with intravenous colistin treatment. International Journal of Antimicrobial Agents. 2010;35(5):473-477.
21. Omrani AS, Alannah WA, Shoukri MM, Baadani AM, Aldalbahi S, Almitwazi AA, et al. High dose intravenous colistin methanesulfonate therapy is associated with high rates of nephrotoxicity; a prospective cohort study from Saudi Arabia. Annals of Clinical Microbiology and Antimicrobials. 2015;14(1):1-6.
22. Rauf M, Akhtar N, Altaf A. Prevalence of acute kidney injury in patients treated with intravenous colistin. Pakistan Journal of Surgery. 2018;34(3):196-199.
23. Horkan CM, Purtle SW, Menedi ML, Moromizato T, Gibbons FK, Christopher KB. The association of acute kidney injury in the critically ill and postdischarge outcomes: A cohort study. Critical Care Medicine. 2015;43(2):354-364.
24. Chao CT, Tsai HB, Lin YF, Ko WJ. Acute kidney injury in the elderly: only the tip of the iceberg. Journal of Clinical Gerontology and Geriatrics. 2014;5(1):7-12.
25. Rodrigo E, Suberviola B, Santibáñez M, Belmar L, Castellanos A, Heras M, et al. Association between recurrence of acute kidney injury and mortality in intensive care unit patients with severe sepsis. Journal of Intensive Care. 2017;5(1):1-8.
26. Almutairy R, Aljarri W, Noor A, Elsamadisi P, Shamas N, Qureshi M, et al. Impact of Colistin Dosing on the Incidence of Nephrotoxicity in a Tertiary Care Hospital in Saudi Arabia. Antibiotics. 2020;9(8):485.

27. DeRyke CA, Crawford AJ, Uddin N, Wallace MR. Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrobial Agents and Chemotherapy. 2010;54(10):4503-4505.

© 2021 Arif et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
http://www.sdiarticle4.com/review-history/66502